TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: Effectiveness of Nicotine patch only; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch | Arm Label: Effectiveness of Combination NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine lozenge, Drug: Nicotine Patch | Arm Label: Effectiveness of Varenicline [Chantix]; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Effectiveness of Varenicline [Chantix] | Intervention Type: DRUG; Name: Nicotine lozenge; Assigned to Arm(s): Effectiveness of Combination NRT | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Effectiveness of Combination NRT, Effectiveness of Nicotine patch only
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 4 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating The Efficacy And Safety Of Re-Treatment With Varenicline In Subjects Who Are Currently Smoking, And Who Have Previously Taken Varenicline
Brief Summary: The main purpose of this study is to compare the effectiveness and safety of the re-treatment of smokers with varenicline with placebo for smoking cessation during the last 4 weeks of a 12 week course of treatment. The study will also assess whether smokers remain abstinent at Week 24 (12 weeks after the end of treatment) and Week 52 (40 weeks after the end of treatment).


Options:
A: Arm Label: Brief Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Tailored/No Extended NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Arm Label: Extended Tailored Counseling + NRT; Type: EXPERIMENTAL; Interventions: Drug: Nicotine polacrilex, Bupropion | Intervention Type: DRUG; Name: Nicotine polacrilex, Bupropion; Assigned to Arm(s): Brief Treatment, Extended NRT, Extended Tailored Counseling + NRT, Tailored/No Extended NRT
B: Intervention Type: DRUG; Name: CP-526,555 (varenicline); Assigned to Arm(s): N/A
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Varenicline + Active Patch; Type: EXPERIMENTAL; Interventions: Drug: Nicotine Patch, Drug: Varenicline | Arm Label: Varenicline + Placebo Patch; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Varenicline | Intervention Type: DRUG; Name: Nicotine Patch; Assigned to Arm(s): Varenicline + Active Patch | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Varenicline + Placebo Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline + Active Patch, Varenicline + Placebo Patch

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lifestyle Improvement Through Food and Exercise (LIFE): Self-Management in African Americans With Diabetes and Hypertension
Brief Summary: The primary aim of the study is to design a group-based, culturally appropriate self-management skills training intervention for disadvantaged African-Americans with both diabetes and hypertension and to compile an intervention Manual of Operations (MOO). The investigators are developing an intervention to assist individuals in reducing weight and hemoglobin A1c.


Options:
A: Arm Label: Patient Navigator; Type: EXPERIMENTAL; Interventions: Other: Patient Navigator, Other: Usual care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient Navigator; Assigned to Arm(s): Patient Navigator | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Patient Navigator
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive diabetes self-management education | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard diabetes education | Intervention Type: BEHAVIORAL; Name: Intensive diabetes self-management education; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard diabetes education; Assigned to Arm(s): Control Group
C: Arm Label: Electronic (USB) Portable Health File; Type: EXPERIMENTAL; Interventions: Device: Electronic (USB) Portable Health File | Arm Label: Paper Portable Health File; Type: EXPERIMENTAL; Interventions: Device: Paper Portable Health File | Arm Label: Usual standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic (USB) Portable Health File; Assigned to Arm(s): Electronic (USB) Portable Health File | Intervention Type: DEVICE; Name: Paper Portable Health File; Assigned to Arm(s): Paper Portable Health File
D: Arm Label: Community-based nurse care management; Type: EXPERIMENTAL; Interventions: Other: Community-based nurse care management | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Community-based nurse care management; Assigned to Arm(s): Community-based nurse care management

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Lifestyle Improvement Through Food and Exercise (LIFE): Self-Management in African Americans With Diabetes and Hypertension
Brief Summary: The primary aim of the study is to design a group-based, culturally appropriate self-management skills training intervention for disadvantaged African-Americans with both diabetes and hypertension and to compile an intervention Manual of Operations (MOO). The investigators are developing an intervention to assist individuals in reducing weight and hemoglobin A1c.


Options:
A: Arm Label: SSRI + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: SSRI + placebo | Arm Label: Escitalopram + Bupropion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Escitalopram + Bupropion SR | Arm Label: Venlafaxine XR + Mirtazapine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Venlafaxine XR + Mirtazapine | Intervention Type: DRUG; Name: SSRI + placebo; Assigned to Arm(s): SSRI + placebo | Intervention Type: DRUG; Name: Escitalopram + Bupropion SR; Assigned to Arm(s): Escitalopram + Bupropion SR | Intervention Type: DRUG; Name: Venlafaxine XR + Mirtazapine; Assigned to Arm(s): Venlafaxine XR + Mirtazapine
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive diabetes self-management education | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard diabetes education | Intervention Type: BEHAVIORAL; Name: Intensive diabetes self-management education; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard diabetes education; Assigned to Arm(s): Control Group
C: Arm Label: Psychoeducative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducative intervention; Assigned to Arm(s): Psychoeducative intervention
D: Arm Label: CHAP-EMS/CP@clinic Program Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: CHAP-EMS/CP@clinic | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CHAP-EMS/CP@clinic; Assigned to Arm(s): CHAP-EMS/CP@clinic Program Intervention

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Supplementations as Adjunct to Anti-tuberculosis Drugs in Mongolia
Brief Summary: The investigators proposed a pilot study preparatory to developing a randomized trial of vitamin D for the prevention of TB infection. The specific aims are presented below:

1. To recruit subjects, obtain consent, distribute vitamin D supplements to the children in the schools, obtain blood samples and transport them to the United States.
2. To test the hypothesis that daily vitamin D supplementation will increase plasma levels of 25(OH)D, and restore TLR-induced antimicrobial activity in monocytes/macrophages tested in vitro.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: No supplementation | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: No supplementation; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): 3
B: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol, Dietary Supplement: Calcium, Dietary Supplement: Calcium and cholecalciferol, Drug: Placebo | Arm Label: Calcium; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol, Dietary Supplement: Calcium, Dietary Supplement: Calcium and cholecalciferol, Drug: Placebo | Arm Label: Cholecalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol, Dietary Supplement: Calcium, Dietary Supplement: Calcium and cholecalciferol, Drug: Placebo | Arm Label: Calcium and cholecalciferol; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Cholecalciferol, Dietary Supplement: Calcium, Dietary Supplement: Calcium and cholecalciferol, Drug: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol; Assigned to Arm(s): Calcium, Calcium and cholecalciferol, Cholecalciferol, Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium; Assigned to Arm(s): Calcium, Calcium and cholecalciferol, Cholecalciferol, Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium and cholecalciferol; Assigned to Arm(s): Calcium, Calcium and cholecalciferol, Cholecalciferol, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Calcium, Calcium and cholecalciferol, Cholecalciferol, Placebo
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin D | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
D: Arm Label: Vitamin D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D; Assigned to Arm(s): Vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry
Brief Summary: The purpose of the study is to assess the efficacy of amoxicillin-clavulanate in treating acute otitis media in children. The primary end point is time to disappearance of middle ear effusion which monitored by daily tympanometry performed by families and study physicians.


Options:
A: Intervention Type: BEHAVIORAL; Name: Prescription Fill Status; Assigned to Arm(s): N/A
B: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate, Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Oral Amoxicillin-clavulanate in Treating Acute Otitis Media in Children: Randomized Double-blind Placebo-controlled Study Including Daily Monitoring With Tympanometry
Brief Summary: The purpose of the study is to assess the efficacy of amoxicillin-clavulanate in treating acute otitis media in children. The primary end point is time to disappearance of middle ear effusion which monitored by daily tympanometry performed by families and study physicians.


Options:
A: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BEHAVIORAL; Name: Prescription Fill Status; Assigned to Arm(s): N/A
C: Arm Label: Amoxicillin-clavulanate; Type: EXPERIMENTAL; Interventions: Drug: Amoxicillin-clavulanate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amoxicillin-clavulanate, Drug: Placebo | Intervention Type: DRUG; Name: Amoxicillin-clavulanate; Assigned to Arm(s): Amoxicillin-clavulanate, Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: amoxicillin-clavulanate | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: amoxicillin-clavulanate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Life Goals Behavioral Change to Improve Outcomes for Veterans With SMI
Brief Summary: Persons with serious mental illness are at increased risk of cardiovascular disease. The goals of this study are to test a treatment, Life Goals Collaborative Care to help promote health behavior change and to get feedback from patients and providers on what is needed to help better coordinate and physical and mental health care of these patients.


Options:
A: Arm Label: IDEAL intervention; Type: EXPERIMENTAL; Interventions: Other: IDEAL intervention | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: IDEAL intervention; Assigned to Arm(s): IDEAL intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
B: Arm Label: SIMPLe 2.0 plus Treatment as Usual (TAU); Type: EXPERIMENTAL; Interventions: Device: SIMPLE 2.0 | Arm Label: Treatment as usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: SIMPLE 2.0; Assigned to Arm(s): SIMPLe 2.0 plus Treatment as Usual (TAU)
C: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: Life Goals Collaborative Care | Intervention Type: BEHAVIORAL; Name: Life Goals Collaborative Care; Assigned to Arm(s): Arm 1
D: Arm Label: Integrated Treatment; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Treatment | Arm Label: Community Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Community Care | Intervention Type: BEHAVIORAL; Name: Integrated Treatment; Assigned to Arm(s): Integrated Treatment | Intervention Type: BEHAVIORAL; Name: Community Care; Assigned to Arm(s): Community Care

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Trial of a Water Beverage Intervention Trial for Reducing Risk Factors of Metabolic Syndrome in Young Mexican Free Living Women
Brief Summary: Research Question: Does replacing Sugar Sweetened (SS) beverages with water consumption promote a decrease in triglycerides blood levels over 9 months in overweight women? The primary outcome variable is the triglycerides blood level. In addition, the investigators will consider as secondary outcome variables the following parameters of metabolic syndrome: weight, fasting insulin and glucose, HOMA, HDL-cholesterol, systolic and diastolic blood pressure, and waist circumference. The investigators will also consider as an outcome variable glycosylated (or glycated) hemoglobin (HbA1c).

Design: Two groups randomized controlled trial, with an intervention group (water and education provision) and control group (education provision only).

The investigators propose to recruit young adult women aged \>18-\<45 y who are overweight or obese (BMI \>25 and \<39), and consume at least 250 calories per day from caloric beverages (e.g., includes soft drinks, juices, sports drinks, sweetened tea or coffee, and alcoholic beverages) The intervention group (water and education provision) will be compared with a control condition (education provision only). The intervention has been proposed to be carried out for 9 months period with objective measurements of body weight and fat, total cholesterol, LDL-C, HDL-C, fasting blood glucose, HbA1C, hydration status, blood pressure, and 24 hrs dietary recalls at baseline, 3,6 and 9 months


Options:
A: Arm Label: Water; Type: EXPERIMENTAL; Interventions: Other: Water | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Other: Education | Intervention Type: OTHER; Name: Water; Assigned to Arm(s): Water | Intervention Type: OTHER; Name: Education; Assigned to Arm(s): Control
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Behavioral: environmental and behavioral change | Intervention Type: BEHAVIORAL; Name: environmental and behavioral change; Assigned to Arm(s): Intervention group
C: Arm Label: School based intervention; Type: EXPERIMENTAL; Interventions: Behavioral: integrated program of nutrition, activity, behavior, and promotion | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: integrated program of nutrition, activity, behavior, and promotion; Assigned to Arm(s): School based intervention
D: Arm Label: Feedback only; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback letters | Arm Label: Feedback plus incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Feedback plus incentives | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Feedback letters; Assigned to Arm(s): Feedback only | Intervention Type: BEHAVIORAL; Name: Feedback plus incentives; Assigned to Arm(s): Feedback plus incentives

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Deep Brain Stimulation of the Nucleus Accumbens as a Novel Treatment in Severe Opioid Addiction
Brief Summary: The main objective of this study is to assess the efficacy of bilateral deep brain stimulation (DBS) of the Nucleus accumbens (NAc) as a novel treatment in severe opioid addiction. The included patients have been treated so far with a substitute in form of methadone.

Our hypothesis is that bilateral DBS of the NAc will significantly reduce the craving for heroin and thus enable the patients to decrease their Levomethadone-dosage substantially.


Options:
A: Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Other: Deep brain stimulation | Arm Label: Deep Brain Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Deep brain stimulation | Intervention Type: OTHER; Name: Deep brain stimulation; Assigned to Arm(s): Deep Brain Stimulation, Placebo
B: Arm Label: Deep Brain Stimulation; Type: ACTIVE_COMPARATOR; Interventions: Other: Deep brain stimulation | Arm Label: Placebo; Type: SHAM_COMPARATOR; Interventions: Other: Placebo | Intervention Type: OTHER; Name: Deep brain stimulation; Assigned to Arm(s): Deep Brain Stimulation | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Continuous Deep Brain Stimulation (DBS); Type: EXPERIMENTAL; Interventions: Device: Continuous DBS | Arm Label: Responsive Brain Stimulation (RBS Setting); Type: EXPERIMENTAL; Interventions: Device: Responsive Brain Stimulation (RBS Setting) | Intervention Type: DEVICE; Name: Continuous DBS; Assigned to Arm(s): Continuous Deep Brain Stimulation (DBS) | Intervention Type: DEVICE; Name: Responsive Brain Stimulation (RBS Setting); Assigned to Arm(s): Responsive Brain Stimulation (RBS Setting)
D: Arm Label: ODT; Type: ACTIVE_COMPARATOR; Interventions: Drug: Optimal drug therapy | Arm Label: DBS+ODT; Type: EXPERIMENTAL; Interventions: Device: B-STN DBS, Drug: Optimal drug therapy | Intervention Type: DEVICE; Name: B-STN DBS; Assigned to Arm(s): DBS+ODT | Intervention Type: DRUG; Name: Optimal drug therapy; Assigned to Arm(s): DBS+ODT, ODT

Answer: B